Aradigm Initiates Phase 2 Study Of Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis

Aradigm Corporation (OTCBB:ARDM) announced it has initiated a Phase 2 study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis. This safety and efficacy study follows the successful completion of a Phase 1 safety, tolerability and pharmacokinetics trial in healthy volunteers and the previously executed preclinical toxicology program. [click link for full article]

More: continued here

Filed under: Cystic Fibrosis on December 2nd, 2007